Form 4: AnaptysBio Director Acquires Restricted Stock Units

AnaptysBio, Inc. Director John P. Schmid acquired 6,030 restricted stock units on June 15, 2026, with full vesting scheduled for June 15, 2026.

Summary

• John P. Schmid, a Director at AnaptysBio, Inc., acquired 6,030 restricted stock units (RSUs) on June 15, 2026.
• These RSUs represent a contingent right to receive one share of AnaptysBio's common stock per unit.
• The acquisition was made for no monetary consideration.
• The RSUs are set to vest fully on June 15, 2026, contingent upon Mr. Schmid's continued service to the company on that date.
• Following this transaction, Mr. Schmid beneficially owns 37,652 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It represents a standard equity award to a director, which is typical compensation, rather than a strong signal of insider buying with personal funds or a significant strategic development.

Positives

• Director acquisition of equity signals confidence in the company's future prospects.
• Full vesting of RSUs on a specific near-term date (June 15, 2026) provides a clear incentive and potential for increased shareholder alignment.
• The acquisition of 6,030 RSUs represents a notable addition to the Director's holdings.

Negatives

• The acquisition of RSUs for no consideration is a standard compensation practice and does not represent a purchase using personal funds, which could be seen as a stronger signal of conviction.
• The filing is a Form 4, indicating a change in beneficial ownership, not a new strategic initiative or financial performance update.

Risks

• The vesting of these RSUs is contingent on continued service, meaning any departure from the company before June 15, 2026, would result in forfeiture.
• The value of the acquired RSUs is directly tied to the future stock performance of AnaptysBio, Inc.

Future Outlook

The future outlook is tied to the vesting of the restricted stock units on June 15, 2026, which will increase the Director's direct beneficial ownership, assuming continued service.

Industry Context

StockSavvy.ai notes that insider transactions, such as this acquisition of restricted stock units by a director, are common in the biotechnology sector as a method of executive compensation and incentive alignment. The timing of the vesting is a key factor for investors to monitor.

Corporate Governance

Stakeholder Impact

• Shareholders: The acquisition of RSUs by a director is a standard compensation practice and does not directly impact shareholders in the short term, but it aligns director interests with long-term company performance.
• Employees: This filing is specific to director compensation and does not directly impact other employees.
• Management: The filing pertains to a director's equity award, which is part of the overall executive compensation structure.

Next Steps

• Vesting of 6,030 Restricted Stock Units on June 15, 2026, subject to continued service.
• Potential future filings on Form 4 if further transactions occur.

Key Dates

Keywords

AnaptysBio, ANAB, Form 4, Restricted Stock Units, RSU, Director, Beneficial Ownership, Securities Exchange Act, Insider Trading, Equity Award